Emergent buys Protein Sciences in $75M deal

Emergent BioSolutions has inked a deal to buy 25-year-old Protein Sciences for $75 million or more. Protein Sciences has been developing a new flu vaccine, FluBlok, relying on a new method that grows

Bavarian Nordic launches early trial for HIV vaccine

Denmark's Bavarian Nordic has launched a Phase I/II trial of an experimental HIV vaccine. Safety data from the study is expected by the end of this year with immunogenicity data following in the

SPOTLIGHT: Analyst lengthens timeline for Cervarix

A Morgan Stanley analyst is raising the prospect that GlaxoSmithKline's Cervarix could be delayed five years beyond the 2009 approval expected by most analysts on Wall Street.

ALSO NOTED: Progress on cancer vaccine; Big shoe maker adds vaccines; and much more...

Vaccine Research A team of researchers say that a human protein could play a key role in developing a new cancer vaccine.

Kennedy's best hope may lie in cancer vaccine trial

The general prognosis for anyone diagnosed with malignant glioma is poor. The most common form is glioblastoma multiforme, which swiftly dispatches cancer cells throughout the brain. Patients

Prostate cancer vaccine performs well in early trial

An early-stage trial of an experimental prostate cancer vaccine demonstrated that it was safe and also generated an immune response among a large percentage of the volunteers in the study. A total of

Alzheimer's vaccine spurs immune response in mice

An experimental vaccine developed at the University of Rochester Medical Center prevented the build-up of amyloid plaques in the brains of mice engineered to develop an aggressive form of Alzheimer's

Relenza outperforms Tamiflu in bird flu study

The antiviral Relenza has won a battle over Tamiflu in the competition for government contracts from governments anxious about a possible bird flu epidemic. New research published in Nature

SPOTLIGHT: Virus hunters track flu virus to source

A crew of virus-hunters has found that the flu virus's breeding grounds are in Asia. After starting there it then teems out to take over the world each year.

ALSO NOTED: Flu viruses more resistant; meningitis vaccine successful in trial; and much more...

Vaccine Market Experts told a meeting of the Infectious Diseases Society of America that flu viruses are growing increasingly resistant to antivirals, with Europe seeing some of the greatest

Allergy Therapeutics shares spike on late-stage data

Shares of the UK's Allergy Therapeutics surged on the news that its experimental hay fever vaccine--Pollinex Quattro--demonstrated positive results in a crucial Phase III study, which they say was

Novartis touts mid-stage results for MenB

Novartis says that a mid-stage study of its MenB vaccine demonstrated broad protection from meningococcal B infections in infants. Researchers tracked positive results starting with three

Cervarix data demonstrates prolonged protection

GlaxoSmithKline has released new Cervarix data that demonstrates the vaccine's ability to generate a high and sustained level of antibodies to neutralize the two most prevalent strains of cervical

Vaccine makers to produce record amount of flu jab

The five key vaccine makers say they plan to produce a record 143 million doses of flu vaccine for the U.S. market next season, which should be enough to satisfy demand. Manufacturers delivered 140

SPOTLIGHT: Intercell to acquire Iomai

Austria's Intercell is buying Iomai for $189 million in cash and stock. The deal will add Iomai's patch to prevent traveler's diarrhea and an adjuvant for bird flu vaccine that has produced

ALSO NOTED: Korea blueprints bird flu vaccine factory;HIV researchers vow to pursue vaccine; and much more...

Vaccine Market South Korea says it will build a bird flu vaccine factory next year. And the country says it will stockpile enough Tamiflu to be able to treat 10 million people in the event of a

WHO warns of rising bird flu pandemic risk

The headlines may have died down in recent months, but bird flu experts say that the threat of a global pandemic has actually been growing. The World Health Organization outlined the spread of the

Experts call for long-term immunity tracking studies

Vaccine experts are pondering just how long vaccines will be able to provide immunity in a world where some diseases are all but eliminated and natural exposure to many common viruses has ended.

Researchers explore brain cancer vaccine

Researchers are touting the early results from a study of a new brain cancer vaccine that combines protein antigens extracted from a patient's tumor and matches them with white cells also drawn from

VaxGen sells anthrax vaccine to its old rival

Reduced to a skeleton crew and a bleak outlook, South San Francisco-based VaxGen sold its experimental anthrax vaccine to its former chief rival, Emergent BioSolutions, for $2 million down and up to